TCRX — Tscan Therapeutics Balance Sheet
0.000.00%
- $90.55m
- -$167.49m
- $2.82m
Annual balance sheet for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 34.8 | 161 | 120 | 192 | 290 |
Prepaid Expenses | |||||
Total Current Assets | 36.4 | 166 | 124 | 194 | 293 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 12.5 | 17.3 | 69.2 | 71.2 | 71.6 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 49.7 | 188 | 199 | 272 | 371 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 17.4 | 21.3 | 17.3 | 29.8 | 36 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 32.5 | 27.3 | 99.7 | 121 | 130 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 17.2 | 161 | 99.4 | 151 | 241 |
Total Liabilities & Shareholders' Equity | 49.7 | 188 | 199 | 272 | 371 |
Total Common Shares Outstanding |